The impact of long-acting injectables (LAIs) for HIV was discussed at the 35th ESCMID Global conference in Vienna, Austria.

Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...

Daiichi and AstraZeneca's Enhertu with pertuzumab has shown PFS improvement in the Phase III DESTINY-Breast09 trial.

Enlivex has completed the enrollment of all subjects in the Phase II stage of the Phase I/II trial of Allocetra for severe ...